CoRSeqV3-C: A novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Cashin, Kieran ^a,b   Gray, Lachlan R ^a,c   Jakobsen, Martin R ^a,d   Sterjovski, Jasminka ^a   Churchill, Melissa J ^a,c   Gorry, Paul R ^a,b,c   Gray, Rohan ^e   Roche , Michael ^e  

^a BURNET INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d AARHUS UNIVERSITY   (Denmark)

^e NONE

Author keywords

CCR5; Coreceptor; CXCR4; gp120; HIV 1; Prediction algorithm; subtype C; V3

Indexed keywords

AMINO ACID; CHEMOKINE RECEPTOR CXCR4; GLUTAMIC ACID; GLYCINE; GLYCOPROTEIN GP 120; PROLINE; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS RECEPTOR;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; GENE INSERTION; GENETIC ALGORITHM; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PREDICTION; PROTEIN GLYCOSYLATION; PROTEIN MOTIF; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; VIRUS STRAIN; BIOLOGY; EVALUATION; GENETICS; GENOTYPE; HUMAN; METHODOLOGY; MOLECULAR BIOLOGY; PHYSIOLOGY; VIRAL TROPISM; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

COMPUTATIONAL BIOLOGY; GENOTYPE; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR BIOLOGY; RECEPTORS, HIV; VIRAL TROPISM; VIROLOGY;

EID: 84874270245     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-24     Document Type: Article

References (53)

1. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381(6584):661-666. 10.1038/381661a0, 8649511.
2. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381(6584):667-673. 10.1038/381667a0, 8649512.
3. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272(5263):872-877. 10.1126/science.272.5263.872, 8629022.
4. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85(7):1135-1148. 10.1016/S0092-8674(00)81313-6, 8674119.
5. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA. A new classification for HIV-1. Nature 1998, 391(6664):240. 10.1038/34571, 9440686.
6. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997, 185(4):621-628. 10.1084/jem.185.4.621, 2196142, 9034141.
7. Groot F, van Capel TM, Schuitemaker J, Berkhout B, de Jong EC. Differential susceptibility of naive, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology 2006, 3:52. 10.1186/1742-4690-3-52, 1562438, 16916447.
8. Vergis EN, Mellors JW. Natural history of HIV-1 infection. Infect Dis Clin North Am 2000, 14(4):809-825. v-vi, 10.1016/S0891-5520(05)70135-5, 11144640.
9. Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006, 194(2):238-246. 10.1086/504693, 16779731.
10. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3(11):e442. 10.1371/journal.pmed.0030442, 1664601, 17132052.
11. Jakobsen MR, Ellett A, Churchill MJ, Gorry PR. Viral tropism, fitness and pathogenicity of HIV-1 subtype C. Futur Virol 2010, 5:219-231.
12. Michler K, Connell BJ, Venter WD, Stevens WS, Capovilla A, Papathanasopoulos MA. Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. AIDS Res Hum Retroviruses 2008, 24(5):743-751. 10.1089/aid.2007.0304, 18507530.
13. Connell BJ, Michler K, Capovilla A, Venter WD, Stevens WS, Papathanasopoulos MA. Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. AIDS 2008, 22(7):896-899. 10.1097/QAD.0b013e3282f57f7a, 18427209.
14. Cilliers T, Nhlapo J, Coetzer M, Orlovic D, Ketas T, Olson WC, Moore JP, Trkola A, Morris L. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003, 77(7):4449-4456. 10.1128/JVI.77.7.4449-4456.2003, 150635, 12634405.
15. Kassaye S, Johnston E, McColgan B, Kantor R, Zijenah L, Katzenstein D. Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy. J Acquir Immune Defic Syndr 2009, 50(1):9-18. 10.1097/QAI.0b013e31818ffdff, 2818215, 19295330.
16. Graf T, Pinto AR. The increasing prevalence of HIV-1 subtype C in Southern Brazil and its dispersion through the continent. Virology 2013, 435(1):170-178. 10.1016/j.virol.2012.08.048, 22999094.
17. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49(11):4721-4732. 10.1128/AAC.49.11.4721-4732.2005, 1280117, 16251317.
18. Hunt JS, Romanelli F. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. Pharmacotherapy 2009, 29(3):295-304. 10.1592/phco.29.3.295, 19249948.
19. Gorry PR, Ellett A, Lewin SR. Maraviroc. Kucers' The Use of Antibiotics 2010, 2869-2876. London: Hodder & Stoughton Ltd, Grayson L, Crowe S, McCarthy J, Mills J, Mouton J, Norrby SR, Paterson D, Pfaller M, 6.
20. Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, Chan ES, Heera J, Chapman D, Spritzler J, Reeves JD. Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin Infect Dis 2011, 52(7):925-928. 10.1093/cid/cir072, 3106234, 21427401.
21. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991, 253(5015):71-74. 10.1126/science.1905842, 1905842.
22. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992, 66(11):6777-6780. 240176, 1404617.
23. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, Swanstrom R. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 2002, 76(8):3852-3864. 10.1128/JVI.76.8.3852-3864.2002, 136063, 11907225.
24. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003, 77(24):13376-13388. 10.1128/JVI.77.24.13376-13388.2003, 296044, 14645592.
25. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, Schuitemaker H. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992, 66(5):3183-3187. 241084, 1560543.
26. Recordon-Pinson P, Soulie C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother 2010, 54(8):3335-3340. 10.1128/AAC.00148-10, 2916345, 20530226.
27. Raymond S, Delobel P, Mavigner M, Ferradini L, Cazabat M, Souyris C, Sandres-Saune K, Pasquier C, Marchou B, Massip P. Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr 2010, 53(2):167-175. 10.1097/QAI.0b013e3181c8413b, 19996764.
28. Garrido C, Roulet V, Chueca N, Poveda E, Aguilera A, Skrabal K, Zahonero N, Carlos S, Garcia F, Faudon JL. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 2008, 46(3):887-891. 10.1128/JCM.01611-07, 2268339, 18199789.
29. Dimonte S, Babakir-Mina M, Mercurio F, Di Pinto D, Ceccherini-Silberstein F, Svicher V, Perno CF. Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage. Virus Res 2012, 168(1-2):73-83.
30. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres-Saune K, Cuzin L, Marchou B, Massip P, Izopet J. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008, 22(14):F11-F16. 10.1097/QAD.0b013e32830ebcd4, 18753930.
31. Delgado E, Fernandez-Garcia A, Vega Y, Cuevas T, Pinilla M, Garcia V, Sanchez M, Gonzalez M, Sanchez AM, Thomson MM. Evaluation of genotypic tropism prediction tests compared with in vitro co-receptor usage in HIV-1 primary isolates of diverse subtypes. J Antimicrob Chemother 2012, 67(1):25-31. 10.1093/jac/dkr438, 22010208.
32. Singh A, Page T, Moore PL, Allgaier RL, Hiramen K, Coovadia HM, Walker BD, Morris L, Ndung'u T. Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. Virology 2009, 393(1):56-67. 10.1016/j.virol.2009.07.021, 3492694, 19695656.
33. Choge I, Cilliers T, Walker P, Taylor N, Phoswa M, Meyers T, Viljoen J, Violari A, Gray G, Moore PL. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses 2006, 22(5):458-465. 10.1089/aid.2006.22.458, 16706624.
34. McCormack GP, Glynn JR, Crampin AC, Sibande F, Mulawa D, Bliss L, Broadbent P, Abarca K, Ponnighaus JM, Fine PE. Early evolution of the human immunodeficiency virus type 1 subtype C epidemic in rural Malawi. J Virol 2002, 76(24):12890-12899. 10.1128/JVI.76.24.12890-12899.2002, 136717, 12438614.
35. Ndung'u T, Sepako E, McLane MF, Chand F, Bedi K, Gaseitsiwe S, Doualla-Bell F, Peter T, Thior I, Moyo SM. HIV-1 subtype C in vitro growth and coreceptor utilization. Virology 2006, 347(2):247-260. 10.1016/j.virol.2005.11.047, 16406460.
36. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007, 25(12):1407-1410. 10.1038/nbt1371, 18066037.
37. Jensen MA, Coetzer M, van 't Wout AB, Morris L, Mullins JI. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 2006, 80(10):4698-4704. 10.1128/JVI.80.10.4698-4704.2006, 1472078, 16641263.
38. Shioda T, Levy JA, Cheng-Mayer C. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1992, 89(20):9434-9438. 10.1073/pnas.89.20.9434, 50146, 1409653.
39. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 2007, 23(3):415-426. 10.1089/aid.2006.0130, 17411375.
40. Rosen O, Sharon M, Quadt-Akabayov SR, Anglister J. Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Proc Natl Acad Sci U S A 2006, 103(38):13950-13955. 10.1073/pnas.0606312103, 1599894, 16966601.
41. Lin NH, Becerril C, Giguel F, Novitsky V, Moyo S, Makhema J, Essex M, Lockman S, Kuritzkes DR, Sagar M. Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. Virology 2012, 433(2):296-307. 10.1016/j.virol.2012.08.013, 22954962.
42. Coetzer M, Cilliers T, Ping LH, Swanstrom R, Morris L. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology 2006, 356(1-2):95-105.
43. Brelot A, Heveker N, Adema K, Hosie MJ, Willett B, Alizon M. Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J Virol 1999, 73(4):2576-2586. 104012, 10074102.
44. Doranz BJ, Lu ZH, Rucker J, Zhang TY, Sharron M, Cen YH, Wang ZX, Guo HH, Du JG, Accavitti MA. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol 1997, 71(9):6305-6314. 191903, 9261347.
45. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310(5750):1025-1028. 10.1126/science.1118398, 2408531, 16284180.
46. Pollakis G, Abebe A, Kliphuis A, Chalaby MI, Bakker M, Mengistu Y, Brouwer M, Goudsmit J, Schuitemaker H, Paxton WA. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol 2004, 78(6):2841-2852. 10.1128/JVI.78.6.2841-2852.2004, 353763, 14990703.
47. Polzer S, Dittmar MT, Schmitz H, Schreiber M. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 2002, 304(1):70-80. 10.1006/viro.2002.1760, 12490404.
48. Clevestig P, Pramanik L, Leitner T, Ehrnst A. CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. J Gen Virol 2006, 87(Pt 3):607-612.
49. Nabatov AA, Pollakis G, Linnemann T, Kliphius A, Chalaby MI, Paxton WA. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 2004, 78(1):524-530. 10.1128/JVI.78.1.524-530.2004, 303404, 14671134.
50. Coetzer M, Nedellec R, Cilliers T, Meyers T, Morris L, Mosier DE. Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J Acquir Immune Defic Syndr 2011, 56(1):9-15. 10.1097/QAI.0b013e3181f63906, 3006070, 20921899.
51. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006, 80(2):750-758. 10.1128/JVI.80.2.750-758.2006, 1346864, 16378977.
52. Thielen A, Lengauer T, Swenson LC, Dong WW, McGovern RA, Lewis M, James I, Heera J, Valdez H, Harrigan PR. Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially. Antivir Ther 2011, 16(3):319-328. 10.3851/IMP1769, 21555814.
53. Delobel P, Sandres-Saune K, Cazabat M, Pasquier C, Marchou B, Massip P, Izopet J. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005, 38(4):382-392. 10.1097/01.qai.0000152835.17747.47, 15764954.